Confirmed Sponsors & Exhibitors

Confirmed Sponsors & Exhibitors

Thank you to our sponsors and exhibitors for supporting the 4th Annual Congress of Liquid Biopsy (ISLB 2022)

DIAMOND LEVEL

Guardant

PLATINUM LEVEL

Foundation Medicine

AstraZeneca

SILVER LEVEL

Natera

Thermo Fisher

Menarini Silicon Biosystems

Regeneron

EMD Serono

BRONZE LEVEL

Sermonix Pharmaceuticals

Bio-Rad Laboratories

Blueprint Medicines

Genomics

Exhibitors 

Amgen

Amgen is a worldwide leader in biotechnology. For more than forty years, we’ve pursued some of the greatest challenges facing human health, marrying science and technological innovation with the passion of our staff, to serve patients and find new solutions that meet the growing demand for better quality healthcare for more people worldwide. (amgen.com)

ANGLE

ANGLE is a world-leading liquid biopsy company with offices in Guildford (UK), Toronto (Canada) and Greater Philadelphia (USA). ANGLE’s Parsortix® PC1 Clinical System is the first

FDA cleared medical device for the capture and harvest of intact circulating tumor cells from metastatic breast cancer patient blood for subsequent, user-validated analysis. (angleplc.com)

Tell me more

Bayer

Bayer is a global life sciences leader in healthcare and nutrition. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing therapies and delivering first-in-class educational and support programs to meet their needs.   For more information, visit (bayer.us)

Biodesix

Biodesix’ mission is to unite biopharma, physicians, and patients to transform the standard of care and improve outcomes with personalized diagnostics. We envision a world where all critical diseases are diagnosed early and treated quickly with the guidance of personalized diagnostic solutions, so humanity can thrive without the burden of disease. (biodesix.com)

Boehringer Ingelheim

At Boehringer Ingelheim, we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. (boehringer-ingelheim.us)

BioFluidica

We are a privately held biotechnology company that has developed an automated liquid biopsy platform for isolating and enriching rare circulating cells (e.g., circulating tumor cells, CTCs) and exosomes. The platform is based on microfluidic chip devices having antibody surfaced micro-channels. These chips then serve as affinity “catch-and-release” to specifically enrich biomarkers of clinical or research interest from liquid biopsy. (biofluidica.com)

Bio-Rad Laboratories

Bio-Rad is a global leader for life science research and clinical diagnostics that advance several applications for liquid biopsy. For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification. Celselect Slide™ Technology with the Genesis System enables CTC enrichment and enumeration applications. (bio-rad.com)

Tell me more

BostonGene

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. (bostongene.com)

Caris Life Sciences

Caris Life Sciences® is the leading molecular science and technology company developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins, revealing a molecular blueprint helping physicians better detect, diagnose and treat patients. (CarisLifeSciences.com)

Foundation Medicine

Foundation Medicine’s highly validated portfolio of comprehensive genomic profiling tests provides clinically-relevant genomic results for all advanced cancer patients regardless of specimen type. Find out more about the first FDA-approved test for solid tumors, our liquid biopsy for solid tumors, and our test for hematologic malignancies at foundationmedicine.com/genomic-testing.(foundationmedicine.com)

Tell me more

Genentech

For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California. (gene.com)

Tell me more

Guardant

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. (guardanthealth.com)

Tell me more

Lucence

Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment. Headquartered in Palo Alto, Lucence supplies personalized cancer care services through twin CLIA-licensed laboratories in the United States and Singapore. (lucence.com)

Menarini Silicon Biosystems

Menarini Silicon Biosystems’ new Circulating Multiple Myeloma Cell (CMMC) Assay captures and enumerates CMMCs from peripheral blood and provides a minimally invasive tool to study multiple myeloma and precursor disease states. Through groundbreaking technology and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for many conditions. (siliconbiosystems.com)

Tell me more

Natera

Signatera is a personalized, tumor-informed ctDNA assay for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera is optimized to detect low levels of ctDNA, to help stratify high risk patients and optimize patient management. Discover more at: ww.natera.com/oncology/signatera-advanced-cancer-detection (natera.com)

Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. (novartis.com)

Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. (pfizer.com)

Tell me more

Tempus

Data-driven precision medicine.Bringing the power of data and artificial intelligence to healthcare. (tempus.com)

Tethis S.p.A.

Tethis S.p.A. introduces automation and standardization in the pre-analytical phase of liquid biopsy for cancer diagnostics through its proprietary platform See.d and SBS nanocoated slides, providing the highest quality and integrity of liquid biopsy specimens (plasma and cellular fraction), and enabling the exploitation of multi-biomarkers analysis for precise cancer management. (tethis-lab.com)

Tell me more

Exhibit Floor Plan

CONTACTS

Dr. Oloriz, 16 Street
CP 18012 Granada - Spain

welcome@islb.info

+43 1 3950 6191
(when asked for extension please enter: 303)

Privacy policy

Legal

© 2022 - ISLB | designed & powered by publics iCC